In colorectal cancer (CRC) patients (n = 30) receiving pembrolizumab combined with FOLFOX6, CR/PR patients had lower baseline levels of LAG3+PD-1+CD8+T cells, and patients below the median level of LAG3+PD-1+CD8+T cells exhibited better PFS [94]. This evidence concerns the gene CD8A and colorectal carcinoma.